It was reported that reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia 54, and simultaneous high expressions of SLC31A1 and ABCG2 are associated with poor survival of HNSCC patients 50. This evidence concerns the gene SLC31A1 and chronic myelogenous leukemia, BCR-ABL1 positive.